Macrophage Activation Syndrome and COVID-19

Overview

Journal Inflamm Regen

Publisher Biomed Central

Date 2020 Aug 25

PMID 32834892

Citations 77

Authors

Ryo Otsuka

Ken-Ichiro Seino

Affiliations

Soon will be listed here.

Abstract

An emerging, rapidly spreading coronavirus SARS-CoV-2 is causing a devastating pandemic. As we have not developed curative medicine and effective vaccine, the end of this life-threatening infectious disease is still unclear. Severe COVID-19 is often associated with hypercytokinemia, which is typically found in macrophage activation syndrome. SARS-CoV-2 infection causes this strong inflammation within the lung and propagates to respiratory and, ultimately, systemic organ malfunction. Although we have not fully understood the physiological and pathological aspects of COVID-19, current research progress indicates the effectiveness of anti-cytokine therapy. Here, we summarize macrophage activation syndrome and its possible contribution to COVID-19, and cytokine targeted attempts in severe COVID-19 cases.

Citing Articles

Dynamics of cytokine and antibody responses in community versus hospital SARS-CoV-2 infections.

Singh T, Macintyre A, Burke T, Anderson J, Petzold E, Stover E Front Immunol. 2024; 15:1468871.

PMID: 39650666 PMC: 11621060. DOI: 10.3389/fimmu.2024.1468871.

Macrophage activation syndrome in Sepsis: from pathogenesis to clinical management.

Chen S, Zhang C, Luo J, Lin Z, Chang T, Dong L Inflamm Res. 2024; 73(12):2179-2197.

PMID: 39404874 DOI: 10.1007/s00011-024-01957-7.

The sharp edge of immunosuppressive treatments: infections.

Ozsahin A, Ilgar T, Mahmutoglu Colak S, Akyuz K, Gozukara M, Kostakoglu U Turk J Med Sci. 2024; 54(4):752-760.

PMID: 39295623 PMC: 11407327. DOI: 10.55730/1300-0144.5845.

Immunological characterization and comparison of children with COVID-19 from their adult counterparts at single-cell resolution.

Jia R, Li Z, Hu S, Chang H, Zeng M, Liu P Front Immunol. 2024; 15:1358725.

PMID: 39148728 PMC: 11325098. DOI: 10.3389/fimmu.2024.1358725.

Macrophage Activation Syndrome in Viral Sepsis.

Papageorgiou D, Gogos C, Akinosoglou K Viruses. 2024; 16(7).

PMID: 39066167 PMC: 11281345. DOI: 10.3390/v16071004.

References

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F . Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020; 19(7):102568. PMC: 7252115. DOI: 10.1016/j.autrev.2020.102568. View

Flammiger A, Fiedler W, Bacher U, Bokemeyer C, Schneider M, Binder M . Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment. Acta Haematol. 2012; 128(2):69-72. DOI: 10.1159/000338179. View

Das R, Guan P, Sprague L, Verbist K, Tedrick P, An Q . Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016; 127(13):1666-75. PMC: 4817310. DOI: 10.1182/blood-2015-12-684399. View

Meduri G, Headley S, Kohler G, Stentz F, Tolley E, Umberger R . Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest. 1995; 107(4):1062-73. DOI: 10.1378/chest.107.4.1062. View

Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y . Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005; 202(3):415-24. PMC: 2213088. DOI: 10.1084/jem.20050828. View

Prencipe G, Caiello I, Pascarella A, Grom A, Bracaglia C, Chatel L . Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. J Allergy Clin Immunol. 2017; 141(4):1439-1449. DOI: 10.1016/j.jaci.2017.07.021. View

Dong J, Fujii S, Imagawa S, Matsumoto S, Matsushita M, Todo S . IL-1 and IL-6 induce hepatocyte plasminogen activator inhibitor-1 expression through independent signaling pathways converging on C/EBPdelta. Am J Physiol Cell Physiol. 2006; 292(1):C209-15. DOI: 10.1152/ajpcell.00157.2006. View

10.

Xu X, Han M, Li T, Sun W, Wang D, Fu B . Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020; 117(20):10970-10975. PMC: 7245089. DOI: 10.1073/pnas.2005615117. View

11.

Avau A, Matthys P . Therapeutic Potential of Interferon-γ and Its Antagonists in Autoinflammation: Lessons from Murine Models of Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome. Pharmaceuticals (Basel). 2015; 8(4):793-815. PMC: 4695810. DOI: 10.3390/ph8040793. View

12.

Cavalli G, Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D . Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020; 2(6):e325-e331. PMC: 7252085. DOI: 10.1016/S2665-9913(20)30127-2. View

13.

Huang X, Xiu H, Zhang S, Zhang G . The Role of Macrophages in the Pathogenesis of ALI/ARDS. Mediators Inflamm. 2018; 2018:1264913. PMC: 5989173. DOI: 10.1155/2018/1264913. View

14.

Billiau A, Roskams T, van Damme-Lombaerts R, Matthys P, Wouters C . Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood. 2004; 105(4):1648-51. DOI: 10.1182/blood-2004-08-2997. View

15.

Malmgaard L, Melchjorsen J, Bowie A, Mogensen S, Paludan S . Viral activation of macrophages through TLR-dependent and -independent pathways. J Immunol. 2004; 173(11):6890-8. DOI: 10.4049/jimmunol.173.11.6890. View

16.

Sonmez H, Demir S, Bilginer Y, Ozen S . Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol. 2018; 37(12):3329-3335. DOI: 10.1007/s10067-018-4095-1. View

17.

McGonagle D, ODonnell J, Sharif K, Emery P, Bridgewood C . Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020; 2(7):e437-e445. PMC: 7252093. DOI: 10.1016/S2665-9913(20)30121-1. View

18.

Shimizu M, Mizuta M, Okamoto N, Yasumi T, Iwata N, Umebayashi H . Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2020; 18(1):2. PMC: 6954608. DOI: 10.1186/s12969-020-0399-1. View

19.

Bar-On Y, Flamholz A, Phillips R, Milo R . SARS-CoV-2 (COVID-19) by the numbers. Elife. 2020; 9. PMC: 7224694. DOI: 10.7554/eLife.57309. View

20.

Buonuomo P, Campana A, Insalaco A, Bracaglia C, Pardeo M, Cortis E . Necrotizing fasciitis in a pediatric patient treated with etanercept and cyclosporine for macrophage activation syndrome. Rheumatol Int. 2011; 33(4):1097-8. DOI: 10.1007/s00296-011-2319-7. View